How to buy Biogen (BIIB) stocks

Biogen is a drug manufacturers - general business based in the US. Biogen shares (BIIB) are listed on the NASDAQ and all prices are listed in US Dollars.

Its last market close was $146.47 – a decrease of 2.37% over the previous week. Biogen employs 7,570 staff and has a trailing 12-month revenue of around $9.6 billion.

Our top picks for where to buy Biogen stock

Buy Biogen stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Biogen stock price (NASDAQ: BIIB)

Use our graph to track the performance of BIIB stocks over time.

Biogen stocks at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$146.47
52-week range	$145.24 - $268.30
50-day moving average more info button	$170.36
200-day moving average more info button	$202.44
Wall St. target price	$245.19
PE ratio more info button	13.2842
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$11.05

Is it a good time to buy Biogen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Biogen price performance over time

Historical closes compared with the close of $147.39 from 2024-12-19

1 week (2024-12-13)	-1.76%
1 month (2024-11-21)	-6.72%
3 months (2024-09-20)	-26.07%
6 months (2024-06-21)	-34.20%

1 year (2023-12-21)	-41.94%
2 years (2022-12-21)	-48.62%
3 years (2021-12-21)	234.65
5 years (2019-12-20)	301.05

Is Biogen stock undervalued or overvalued?

Valuing Biogen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biogen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Biogen's P/E ratio

Biogen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Biogen shares trade at around 13x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stock or simply that they're under-valued.

Biogen's PEG ratio

Biogen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.2424. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Biogen's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Biogen's EBITDA

Biogen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.9 billion.

The EBITDA is a measure of a Biogen's overall financial performance and is widely used to measure a its profitability.

Biogen financials

Revenue TTM	$9.6 billion
Operating margin TTM	20.74%
Gross profit TTM	$7.9 billion
Return on assets TTM	4.99%
Return on equity TTM	10.47%
Profit margin	16.81%
Book value	$112.28
Market Capitalization more info button	$21.4 billion

TTM: trailing 12 months

Biogen stock dividends

We're not expecting Biogen to pay a dividend over the next 12 months.

Have Biogen's stocks ever split?

Biogen's stocks were split on a 3:1 basis on 17 January 2001 . So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Biogen stocks – just the quantity. However, indirectly, the new 66.7% lower stock price could have impacted the market appetite for Biogen stocks, which in turn could have impacted Biogen's stock price.

Biogen stock price volatility

Over the last 12 months, Biogen's stocks have ranged in value from as little as $145.24 up to $268.3. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biogen's is -0.061. This would suggest that Biogen's stocks have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Biogen has bucked the trend.

Biogen overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Biogen is owned by insiders or institutions?
Currently 0.153% of Biogen stocks are held by insiders and 93.467% by institutions. How many people work for Biogen?
Latest data suggests 7,570 work at Biogen. When does the fiscal year end for Biogen?
Biogen's fiscal year ends in December. Where is Biogen based?
Biogen's address is: 225 Binney Street, Cambridge, MA, United States, 02142 What is Biogen's ISIN number?
Biogen's international securities identification number is: US09062X1037 What is Biogen's CUSIP number?
Biogen's Committee on Uniform Securities Identification Procedures number is: 449370105

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.